The Prospect of Probiotics to Treat Metabolic Syndrome
Abstract
Metabolic syndrome remains as a major health problem in the world today, with a prevalence of 23.4% in people aged 26-82 years. A high-fat, high-carbohydrate diet and lack of physical activity are considered as one of the triggers for metabolic syndrome. Dysbiosis is a condition where there is an imbalance between pathogenic and non-pathogenic bacteria in the human gut. Currently, an association has been found between dysbiosis and metabolic syndrome. Dysbiosis causes the generation of fermentation products in the form of active metabolites that can modulate hormones and other physiological functions. In metabolic syndrome, low-grade inflammation, energy metabolism, and disruption of the gut brain axis are thought to be the main mechanisms of the development of metabolic syndrome due to dysbiosis. Probiotics may be a promising therapeutic agent in the treatment of metabolic syndrome, by improving dysbiosis to eubiosis. Based on previously conducted clinical trials, it is currently known that probiotics can improve lipid profiles, fasting blood glucose, homeostatic model assessment for insulin resistance (HOMA-IR), vascular cell adhesion molecule 1 (VCAM-1), glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and body mass index (BMI). However, the results found are still varied, so a dose ranging study is needed to determine the duration, bacterial composition and dose of probiotics as a therapeutic agent for metabolic syndrome.
Keywords: insulin resistance, dysbiosis, gut-brain axis
Full Text:
PDFReferences
Rustika R, Driyah S, Oemiati R, Hartati N. Prediktor sindrom metabolik: Studi kohor prospektif selama enam tahun di Bogor, Indonesia. Media Penelit Pengemb. 2019; 29(3): 215-24, CrossRef.
Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, et al. Metabolic syndrome: Updates on pathophysiology and management in 2021. Int J Mol Sci. 2022; 23(2): 786, CrossRef.
Backhed F. Host-bacterial mutualism in the human intestine. Science. 2005; 307(5717): 1915-20, CrossRef.
Saad MJ, Santos A, Prada PO. Linking gut microbiota and inflammation to obesity and insulin resistance. Physiology. 2016; 31(4): 283-93, CrossRef.
De Filippis A, Ullah H, Baldi A, Dacrema M, Esposito C, Garzarella EU, et al. Gastrointestinal disorders and metabolic syndrome: Dysbiosis as a key link and common bioactive dietary components useful for their treatment. Int J Mol Sci. 2020; 21(14): 4929, CrossRef.
Anachad O, Taouil A, Taha W, Bennis F, Chegdani F. The implication of short-chain fatty acids in obesity and diabetes. Microbiol Insights. 2023; 16: 11786361231162720, CrossRef.
Green M, Arora K, Prakash S. Microbial medicine: Prebiotic and probiotic functional foods to target obesity and metabolic syndrome. Int J Mol Sci. 2020; 21(8): 2890, CrossRef.
Iebba V, Totino V, Gagliardi A, Santangelo F, Cacciotti F, Trancassini M, et al. Eubiosis and dysbiosis: The two sides of the microbiota. New Microbiol. 2016; 39(1): 1-12, article.
Ghoddusi HB, Tamime AY. Microflora of the intestine: Biology of Bifidobacteria. In: Batt CA, Tortorello ML, editors. Encyclopedia of Food Microbiology, vol 2. Cambridge: Academic Press; 2014. p.639–45, article.
DeGruttola AK, Low D, Mizoguchi A, Mizoguchi E. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis. 2016; 22(5): 1137-50, CrossRef.
Wei S, Bahl MI, Baunwall SMD, Hvas CL, Licht TR. Determining gut microbial dysbiosis: A review of applied indexes for assessment of intestinal microbiota imbalances. Appl Environ Microbiol. 2021; 87(11): e00395-21, CrossRef.
Musso G, Gambino R, Cassader M. Obesity, diabetes, and gut microbiota: The hygiene hypothesis expanded? Diabetes Care. 2010; 33(10): 2277-84, CrossRef.
Gribble FM, Reimann F. Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. Nat Rev Endocrinol. 2019; 15(4): 226-37, CrossRef.
Leeuwendaal NK, Cryan JF, Schellekens H. Gut peptides and the microbiome: Focus on ghrelin. Curr Opin Endocrinol Diabetes Obes. 2021; 28(2): 243-52, CrossRef.
Ríos-Covián D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilán CG, Salazar N. Intestinal short chain fatty acids and their link with diet and human health. Front Microbiol. 2016; 7: 185, CrossRef.
den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013; 54(9): 2325-40, CrossRef.
Dhingra D, Michael M, Rajput H, Patil RT. Dietary fibre in foods: A review. J Food Sci Technol. 2012; 49(3): 255-66, CrossRef.
Cummings JH, Stephen AM. Carbohydrate terminology and classification. Eur J Clin Nutr. 2007; 61(Suppl 1): S5-18, CrossRef.
Breton J, Galmiche M, Déchelotte P. Dysbiotic gut bacteria in obesity: An overview of the metabolic mechanisms and therapeutic perspectives of next-generation probiotics. Microorganisms. 2022; 10(2): 452, CrossRef.
Amabebe E, Robert FO, Agbalalah T, Orubu ESF. Microbial dysbiosis-induced obesity: Role of gut microbiota in homoeostasis of energy metabolism. Br J Nutr. 2020; 123(10): 1127-37, CrossRef.
Tokarek J, Gadzinowska J, Młynarska E, Franczyk B, Rysz J. What is the role of gut microbiota in obesity prevalence? A few words about gut microbiota and its association with obesity and related diseases. Microorganisms. 2021; 10(1): 52, CrossRef.
Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: Underlying causes and modification by exercise training. Compr Physiol. 2013; 3(1): 1-58, CrossRef.
Wondmkun YT. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes Metab Syndr Obes. 2020; 13: 3611-16, CrossRef.
Yazıcı D, Sezer H. Insulin resistance, obesity and lipotoxicity. Adv Exp Med Biol. 2017; 960: 277-304, CrossRef.
Ye J. Mechanisms of insulin resistance in obesity. Front Med. 2013; 7(1): 14-24, CrossRef.
Serra D, Mera P, Malandrino MI, Mir JF, Herrero L. Mitochondrial fatty acid oxidation in obesity. Antioxid Redox Signal. 2013; 19(3): 269-84, CrossRef.
Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res. 2008; 102(4): 401-14, CrossRef.
Bovolini A, Garcia J, Andrade MA, Duarte JA. Metabolic syndrome pathophysiology and predisposing factors. Int J Sports Med. 2021; 42(3): 199-214, CrossRef.
Wang PX, Deng XR, Zhang CH, Yuan HJ. Gut microbiota and metabolic syndrome. Chin Med J. 2020; 133(7): 808-16, CrossRef.
Lukito AA, Bakri S, Kabo P, Wijaya A. The mechanism of coronary artery calcification in centrally obese non-diabetic men: Study on the interaction of leptin, free leptin index, adiponectin, hs-C reactive protein, bone morphogenetic protein-2 and matrix gla protein. Mol Cell Biomed Sci. 2020; 4(2): 88-93, CrossRef.
Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016; 8(1): 42, CrossRef.
van Son J, Koekkoek LL, La Fleur SE, Serlie MJ, Nieuwdorp M. The role of the gut microbiota in the gut-brain axis in obesity: Mechanisms and future implications. Int J Mol Sci. 2021; 22(6): 2993, CrossRef.
Shewale RN, Sawale P, Khedkar C, Singh A. Selection criteria for probiotics: A review. Int J Probiotics Prebiotics. 2014; 9: 17-22, article.
Mallappa RH, Rokana N, Duary RK, Panwar H, Batish VK, Grover S. Management of metabolic syndrome through probiotic and prebiotic interventions. Indian J Endocrinol Metab. 2012; 16(1): 20-7, CrossRef.
Kim YA, Keogh JB, Clifton PM. Probiotics, prebiotics, synbiotics and insulin sensitivity. Nutr Res Rev. 2018; 31(1): 35-51, CrossRef.
Lee HY, Park JH, Seok SH, Baek MW, Kim DJ, Lee KE, et al. Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in diet-induced obese mice. Biochim Biophys Acta. 2006; 1761(7): 736-44, CrossRef.
Lee K, Paek K, Lee HY, Park JH, Lee Y. Antiobesity effect of trans-10,cis-12-conjugated linoleic acid-producing Lactobacillus plantarum PL62 on diet-induced obese mice. J Appl Microbiol. 2007; 103(4): 1140-6, CrossRef.
Kassaian N, Feizi A, Aminorroaya A, Amini M. Probiotic and synbiotic supplementation could improve metabolic syndrome in prediabetic adults: A randomized controlled trial. Diabetes Metab Syndr. 2019; 13(5): 2991-6, CrossRef.
Laue C, Papazova E, Pannenbeckers A, Schrezenmeir J. Effect of a probiotic and a synbiotic on body fat mass, body weight and traits of metabolic syndrome in individuals with abdominal overweight: A human, double-blind, randomised, controlled clinical study. Nutrients. 2023; 15(13): 3039, CrossRef.
Rabiei S, Hedayati M, Rashidkhani B, Saadat N, Shakerhossini R. The effects of synbiotic supplementation on body mass index, metabolic and inflammatory biomarkers, and appetite in patients with metabolic syndrome: A triple-blind randomized controlled trial. J Diet Suppl. 2019; 16(3): 294-306, CrossRef.
Xavier-Santos D, Bedani R, Lima ED, Saad SMI. Impacts of probiotics and prebiotics targeting metabolic syndrome. J Funct Foods. 2020; 64: 103666, CrossRef.
Pluznick J. A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes. 2014; 5(2): 202-7, CrossRef.
Friques AG, Arpini CM, Kalil IC, Gava AL, Leal MA, Porto ML, et al. Chronic administration of the probiotic kefir improves the endothelial function in spontaneously hypertensive rats. J Trans Med. 2015; 13: 390, CrossRef.
Rezazadeh L, Gargari BP, Jafarabadi MA, Alipour B. Effects of probiotic yogurt on glycemic indexes and endothelial dysfunction markers in patients with metabolic syndrome. Nutrition. 2019; 62: 162-8, CrossRef.
Rahimi F, Pasdar Y, Kaviani M, Abbasi S, Fry H, Hekmatdoost A, et al. Efficacy of the synbiotic supplementation on the metabolic factors in patients with metabolic syndrome: A randomized, triple-blind, placebo-controlled trial. Int J Clin Pract. 2022; 2022: 2967977, CrossRef.
Parastouei K, Saeidipoor S, Sepandi M, Abbaszadeh S, Taghdir M. Effects of synbiotic supplementation on the components of metabolic syndrome in military personnel: A double-blind randomised controlled trial. BMJ Mil Health. 2022; 168(5): 362-7, CrossRef.
DOI: https://doi.org/10.21705/mcbs.v8i2.425
Copyright (c) 2024 Cell and BioPharmaceutical Institute
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Indexed by:
Cell and BioPharmaceutical Institute
